PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Cancer Research

• Publication date

  2007-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-06-1609PMID 17575221
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.

  2006cited by this paper
• PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma

  2006cited by this paper
• Mutation of the PIK3CA oncogene in human cancers

  2006cited by this paper
• PIK3CA mutations in breast cancer are associated with poor outcome

  2006cited by this paper
• Cancer-specific mutations in PIK3CA are oncogenic in vivo

  2006cited by this paper
• Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists.

  2006cited by this paper
• Activation of AKT kinases in cancer: implications for therapeutic targeting.

  2005cited by this paper
• Somatic mutation and gain of copy number of PIK3CA in human breast cancer

  2005cited by this paper
• Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

  2005cited by this paper
• PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

  2005cited by this paper
• High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.

  2005cited by this paper
• Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance

  2005cited by this paper
• The prevalence of PIK3CA mutations in gastric and colon cancer.

  2005cited by this paper
• Comparison of phosphatidylinositol‐3‐kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild‐type PIK3CA

  2005cited by this paper
• Mutant PIK3CA promotes cell growth and invasion of human cancer cells.

  2005cited by this paper
• PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas

  2005cited by this paper
• The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.

  2005cited by this paper
• Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers

  2005cited by this paper
• Serum withdrawal kills U937 cells by inducing a positive mutual interaction between reactive oxygen species and phosphoinositide 3-kinase.

  2005cited by this paper
• Reduced Expression of PTEN Protein and Its Prognostic Implications in Invasive Ductal Carcinoma of the Breast

  2005cited by this paper
• The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells

  2005cited by this paper
• The PIK3CA gene is mutated with high frequency in human breast cancers

  2004cited by this paper
• The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome

  2004cited by this paper
• Phospho-Serine-118 Estrogen Receptor-α Expression Is Associated with Better Disease Outcome in Women Treated with Tamoxifen

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• PTEN function: how normal cells control it and tumour cells lose it.

  2004cited by this paper
• PTEN promoter is methylated in a proportion of invasive breast cancers

  2004cited by this paper
• PTEN Gene Targeting Reveals a Radiation-Induced Size Checkpoint in Human Cancer Cells

  2004cited by this paper
• Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

  2004cited by this paper
• Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo.

  2004cited by this paper
• Reduced PTEN Expression Is Associated With Poor Outcome and Angiogenesis in Invasive Ductal Carcinoma of the Breast

  2004cited by this paper
• Phospho-Serine-118 Estrogen Receptor-α Detection in Human Breast Tumors in Vivo

  2004cited by this paper
• Phosphoinositide 3-kinase accelerates autophagic cell death during glucose deprivation in the rat cardiomyocyte-derived cell line H9c2

  2003cited by this paper
• Akt kinases in breast cancer and the results of adjuvant therapy

  2003cited by this paper
• Amplification of HSD17B1 and ERBB2 in primary breast cancer

  2003cited by this paper
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

  2002cited by this paper
• Reduced expression of PTEN correlates with breast cancer progression.

  2002cited by this paper
• Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

  2002cited by this paper
• Regulation of Raf-Akt Cross-talk

  2002cited by this paper
• Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.

  2001cited by this paper
• Phosphoinositide 3-kinase accelerates necrotic cell death during hypoxia.

  2001cited by this paper
• Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α

  2001cited by this paper
• AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells.

  2001cited by this paper
• Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues.

  2001cited by this paper
• Loss of Expression of the PTEN Gene Protein Product Is Associated with Poor Outcome in Breast Cancer

  2001cited by this paper
• Expression of c‐erbB receptors, heregulin and oestrogen receptor in human breast cell lines

  2000cited by this paper
• Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338.

  2000cited by this paper
• Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.

  1999cited by this paper
• c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer.

  1995cited by this paper
• Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials.

  1989cited by this paper

• PTEN and HES1 Gene Expression Alteration in Breast Cancer: Any Association with Tumor Histomorphological Features or Invasive Behavior?

  2025cites this paper
• Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor Approach.

  2025cites this paper
• The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer

  2025cites this paper
• Subtype-specific prognostic implications of plasma-detected PIK3CA mutations in Vietnamese breast cancer patients

  2025cites this paper
• Inositol metabolism as a broad-spectrum antiviral target

  2025cites this paper
• Current and Emerging Diagnostic, Prognostic, and Predictive Biomarkers in Head and Neck Cancer

  2024cites this paper
• Regulatory effects of statins on Akt signaling for prevention of cancers.

  2024cites this paper
• Mutation of PTEN: Loss and Likelihood of Being a Non-responder to Trastuzumab in a Sample of Iraqi Her2+ Breast Cancer Patients

  2024cites this paper
• An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.

  2024cites this paper
• Exploring the Complexity of Pan-Cancer: Gene Convergences and in silico Analyses

  2024cites this paper
• Utilizing PTEN immunohistochemistry as a screening test for Cowden syndrome.

  2024cites this paper
• Characterizing the Tumor Microenvironment and Its Prognostic Impact in Breast Cancer

  2024cites this paper
• Mechanisms of endocrine resistance in hormone receptor-positive breast cancer

  2024cites this paper
• p53 and PTEN expression evaluation with molecular evident recent criteria in laryngeal carcinoma

  2023cites this paper
• Next-Generation Sequencing-Based Analysis of Clinical and Pathological Features of PIK3CA-Mutated Breast Cancer

  2023cites this paper
• SYT7 promotes breast cancer cells growth through the PI3K/AKT pathway

  2023cites this paper
• Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

  2023cites this paper
• Evaluation of PIK3CA Gene Mutations in Breast Cancer Patients Treated by Trastuzumab

  2023cites this paper
• Systemic Therapy for Metastatic Triple Negative Breast Cancer: Current Treatments and Future Directions

  2023cites this paper
• The prognostic importance of PD-L1, PTEN, PHH3, and KI-67 expressions in invasive breast carcinoma

  2022cites this paper
• Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer

  2022cites this paper
• Multi-omics inference of differential breast cancer-related transcriptional regulatory network gene hubs between young Black and White patients.

  2022cites this paper
• A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations

  2022cites this paper
• Overcoming Resistance to HER2-Directed Therapies in Breast Cancer

  2022cites this paper
• The Role of Polymorphic Variants of Gene Components of the PTEN/PI3K/AKT Signaling Pathway in the Development of Prostate Cancer

  2022cites this paper
• Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy

  2022cites this paper
• PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer

  2022cites this paper
• Chip-based digital Polymerase Chain Reaction as quantitative technique for the detection of PIK3CA mutations in breast cancer patients

  2022cites this paper
• TCRM_A_251668 193..207

  2021cites this paper
• Identification of Pathway-Based Biomarkers with Crosstalk Analysis for Overall Survival Risk Prediction in Breast Cancer

  2021cites this paper
• Transcriptomically-inferred PI3K activity and stemness show a 1 counterintuitive correlation with PIK3CA genotype in breast cancer

  2021cites this paper
• Chip-Based Digital Pcr Improves the Detection of Low-Rate pik3ca Mutations in Breast Cancer Patients

  2021cites this paper
• Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives

  2021cites this paper
• Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer

  2021cites this paper
• Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer

  2021cites this paper
• Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020)

  2021cites this paper
• Dysregulation of PI3K/Akt/PTEN Pathway in Canine Mammary Tumor

  2021cites this paper
• Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies.

  2021cites this paper
• Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype

  2021cites this paper
• 1 Transcriptomically-inferred PI 3 K activity and stemness show a 1 counterintuitive correlation with PIK 3 CA genotype in breast cancer 2 3

  2021cites this paper
• PI3K/AKT/MTOR: CONTRIBUTION TO THE TUMOR PHENOTYPE SENSITIVE TO TAMOXIFEN

  2021cites this paper
• The AKT antagonist AZD5363 suppresses features associated with cancer progression in human larynx cancer cells

  2020cites this paper
• PIK3CA mutation profiling in Vietnamese patients with breast cancer

  2020cites this paper
• c-MET as a Potential Resistance Mechanism to Everolimus in Breast Cancer: From a Case Report to Patient Cohort Analysis

  2020cites this paper
• Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations.

  2020cites this paper
• Loss Of Immunohistochemical Expression Of Pten As A Predictive Biomarker In Breast Carcinoma

  2020cites this paper
• Control of Glucocorticoid Receptor Levels by PTEN Establishes a Failsafe Mechanism for Tumor Suppression.

  2020cites this paper
• Somatic mutation profiling in BRCA-negative breast and ovarian cancer patients by multigene panel sequencing.

  2020cites this paper
• PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective

  2020cites this paper
• Role of Coxsackie- and Adenovirus Receptor (CXADR/CAR) in the regulation of cell plasticity in cancer and inflammation

  2020cites this paper
• The Prognostic Significance of Phosphatase and Tensin Homolog Loss in Breast Cancer

  2019cites this paper
• Distinct functions of AKT isoforms in breast cancer: a comprehensive review

  2019cites this paper
• The distinct clinicopathological and prognostic implications of PIK3CA mutations in breast cancer patients from Central China

  2019cites this paper
• The relation between PI3K/AKT signalling pathway and cancer.

  2019cites this paper
• Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

  2019cites this paper
• PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis

  2019influential citation
• PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression

  2019cites this paper
• Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives

  2019cites this paper
• Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine

  2019cites this paper
• Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer

  2019cites this paper
• PTEN in Hereditary and Sporadic Cancer.

  2019cites this paper
• Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer

  2019cites this paper
• Evaluation of PIK3CA Status in Breast Cancer and their Correlation with ER, PR, and HER-2 expressions in Iraqi female patients

  2019cites this paper
• Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer

  2019cites this paper
• 1 The PTEN-PI 3 K axis in cancer 2

  2019cites this paper
• Co-mutation of TP 53 and PIK 3 CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer

  2019cites this paper
• The PTEN–PI3K Axis in Cancer

  2019cites this paper
• Clinical implications of PIK3CA mutations in gliomas molecular subgroups

  2018cites this paper
• Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer

  2018cites this paper
• Role of ESR Pathway Genes in Breast Cancer: A Review

  2018cites this paper
• Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer

  2018cites this paper
• PTEN and p53 Gene Expressions in Breast Cancer Specimens and their Clinicopathological Significance

  2018cites this paper
• Rapamycin enhances the sensitivity of ER‑positive breast cancer cells to tamoxifen by upregulating p73 expression.

  2018cites this paper
• Highlights on molecular targets for radiosensitization of breast cancer cells: Current research status and prospects

  2018cites this paper
• Acquired resistance to aromatase inhibitors: where we stand!

  2018cites this paper
• Tumor PIK3CA genotype and prognosis in early-stage breast cancer A pooled analysis of individual patient data

  2018cites this paper
• Moving Breast Cancer Therapy up a Notch

  2018cites this paper
• Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

  2018cites this paper
• Integrating proteomic and phosphoproteomic data for pathway analysis in breast cancer

  2018cites this paper
• Loss of PTEN Expression Is Associated With High MicroRNA 24 Level and Poor Prognosis in Patients With Tongue Squamous Cell Carcinoma.

  2017cites this paper
• PTENp1, a natural sponge of miR‐21, mediates PTEN expression to inhibit the proliferation of oral squamous cell carcinoma

  2017cites this paper
• The role of Src kinase in regulation of HDAC 3 function Directed by Professor

  2017cites this paper
• PI3K‐AKT‐mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials

  2017cites this paper
• PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer

  2017cites this paper
• Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol

  2017cites this paper
• The prognostic value and potential drug target of phosphatase and tensin homolog in breast cancer patients

  2017influential citation
• Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China

  2017cites this paper
• Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer

  2017cites this paper
• Fibronectin expression is upregulated by PI-3K/Akt activation in tamoxifen-resistant breast cancer cells

  2017cites this paper
• Expression of Phosphoinositide 3-Kinase p110&agr; and p110&bgr; Subunits and PIK3CA Mutation in Patients With Advanced Gastric Carcinoma

  2017cites this paper
• Mutation matters in precision medicine: A future to believe in.

  2017cites this paper
• Cooperating Oncogenic Alterations in Aggressive Pten-Deficient Breast Cancer

  2017cites this paper
• NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis through up-regulation of ATF-4.

  2017cites this paper
• Identification of frequent somatic mutations in inflammatory breast cancer

  2017cites this paper
• Long non-coding RNA PTENP1 inhibits proliferation and migration of breast cancer cells via AKT and MAPK signaling pathways

  2017cites this paper
• Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis

  2017cites this paper
• A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer

  2017cites this paper
• Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer

  2017influential citation
• Classifying cancer genome aberrations by their mutually exclusive effects on transcription

  2017cites this paper
• Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients

  2016cites this paper